RUNX2 and prostate carcinoma: The extensive expression studies demonstrated that the expression level of RUNX2 is aberrantly elevated in numerous cancer tissues as compared to their corresponding normal ones including pancreatic cancer, breast cancer, prostate cancer and osteosarcoma [125].